Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04795141 · ClinicalTrials.gov registry record · Phase 2
ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
A Phase 2 study, sponsored by Inmagene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04795141: Clinical Trial Phase 2 study, sponsored by Inmagene.
NCT04795141 is a Phase 2 study that was terminated before completion, run by Inmagene. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04795141, a Phase 2 study, was terminated before completion, sponsored by Inmagene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing spondylitis(AS). The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 16 in subjects with active AS.
Primary Outcome
The treatment effect
Interventions
- DRUG Placebo
- DRUG ABY-035
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-08-24 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
Why NCT04795141 stopped before completion
NCT04795141 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04795141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04795141 about?
NCT04795141 is a clinical study titled "ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis". ABY-035-204 is a clinical study to assess the efficacy of IL-17 blocker ABY-035 in ankylosing spondylitis(AS). The primary objective is to estimate the relationship between different dose regimens of ABY-035 and clinical response as assessed by Assessment of Spondyloarthritis International Society 4...
What is the current status of trial NCT04795141?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-08-24. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT04795141?
The interventions under investigation include: Placebo (DRUG), ABY-035 (DRUG).
Who is sponsoring clinical trial NCT04795141?
This trial is sponsored by Inmagene, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04795141's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI